Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the ECC Webcasts. By clicking the button below you are declaring and confirming that you are a healthcare professional.

You are here

Closing Remarks

M. De Santis (United Kingdom)

SlotX-6 Closing Remarks

Transcription

Closing Remarks     

I think you have heard a lot about patients and treatment, patient cases.  I think it is important to balance survival and quality of life for our patients and to respect the patients’ wishes and their needs in our treatment decisions.

Full transcription

Full transcription

Closing Remarks     

I think you have heard a lot about patients and treatment, patient cases.  I think it is important to balance survival and quality of life for our patients and to respect the patients’ wishes and their needs in our treatment decisions.

I think that hormone-based therapy being maybe the least toxic will be used as first-line for most mCRPC patients.  For the bone predominant cancers radium-223 could also be an early treatment option, we should not forget that.

We should consider chemotherapy for a high burden of disease, visceral metastases also more up-front but don’t forget that chemotherapy is also important in the treatment paradigm.

No Phase III data are available on the combination and the sequencing still and this remains a difficult field.

The early recognition of resistance is critical.  We did not have the time to go to the particulars of resistance, mainly resistance and what we have heard several times is that more lines of therapy will ensure a better outcome of the patients.

This afternoon:  Meet the Expert session

I would like to encourage you to come to the Meet the Satellite Symposium Expert Session in the evening at 6:30 at the Exhibitor Spotlight Theatre 2.  You will have the opportunity to interact personally to ask your personal questions to the symposium experts, so please come and use this opportunity.

Further on, I would like to ask you to provide your feedback to be able to serve you better in the future meetings.  Fill in the evaluation forms, please and there is a video recording and presentations of this symposium available on the website of the European Journal of Cancer.

With this, I would like to close.  I would like to thank Bayer for giving us the opportunity to discuss for 90 minutes interesting cases of prostate cancer.

I thank you very much for joining us this early afternoon.  We were delighted to have your answers and most of you really used the voting devices.

I wish you all a very exciting remaining afternoon at the ESMO and a very nice evening in Vienna.  Thank you very much for coming.